CABOMETYX

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug CABOMETYX contains one active pharmaceutical ingredient (API):

1 Cabozantinib UNII DR7ST46X58 - CABOZANTINIB S-MALATE

Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, drug resistance, and metastatic progression of cancer. Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors. In addition, cabozantinib inhibits other tyrosine kinases including the GAS6 receptor (AXL), RET, ROS1, TYRO3, MER, the stem cell factor receptor (KIT), TRKB, Fms-like tyrosine kinase-3 (FLT3), and TIE-2. Read about Cabozantinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CABOMETYX Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX07		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11360X, 11367G, 11368H, 11369J, 11371L, 11374P
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 539219010001002, 539219010001102, 539219010001202
Country: CA	Health Products and Food Branch	Identifier(s): 02480824, 02480832, 02480840
Country: EE	Ravimiamet	Identifier(s): 1728840, 1728862, 1728884
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1161136002, 1161136004, 1161136006
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 111502, 118175, 126777
Country: FR	Base de données publique des médicaments	Identifier(s): 66607321, 68164846, 69990857
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 336229, 336232, 336329, 392259, 392276, 392343
Country: HK	Department of Health Drug Office	Identifier(s): 65654, 65655, 65656
Country: IE	Health Products Regulatory Authority	Identifier(s): 88840, 88841, 88842
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8112, 8113, 8114
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291064F1020, 4291064F2026
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1081053, 1081055, 1081057
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 135895, 135909, 135917
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 21186, 21187, 21188
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100377658, 100377664, 100377693
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64527001, W64528001, W64529001
Country: SG	Health Sciences Authority	Identifier(s): 15606P, 15607P, 15608P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699783090449, 8699783090456, 8699783090463
Country: US	FDA, National Drug Code	Identifier(s): 42388-023, 42388-024, 42388-025